Moderna预计去年销售达19亿美元，重申收入增长目标

Core Viewpoint - Vaccine manufacturer Moderna expects sales of approximately $1.9 billion for the previous year, nearing the upper limit of its prior forecast of $1.6 billion to $2 billion, but significantly lower than revenue levels during the pandemic [1] Financial Performance - The company has reduced its 2025 operating expense forecast by $200 million, adjusting the range to $5 billion to $5.2 billion [1] - Moderna anticipates an ending cash balance of $8.1 billion, exceeding the previous forecast of $6.5 billion to $7 billion [1] Future Outlook - The company reaffirms its goal of achieving revenue growth of up to 10% this year [1] - Moderna expects to receive regulatory approval for an independent flu vaccine and a combined flu vaccine this year [1]